Immunostimulatory CpG oligonucleotides reduce tumor burden after intravesical administration in an orthotopic murine bladder cancer model

Tumor Biology

Volumn 26, Issue 5, 2005, Pages 274-280

  Hegele, A ^a,b   Dalpke, A ^a,c   Heeg, K ^a,c   Barth, P ^a   Varga, Z ^a   Hofmann, R ^a   Olbert, P ^a,b  

^a Fachbereich Medizin der Universitat Marburg   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Innate immune system; Instillation therapy; Murine model; Transitional cell cancer

Indexed keywords

BACTERIAL DNA; OLIGONUCLEOTIDE; OLIGONUCLEOTIDE CPG; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; CELL INFILTRATION; CELL SUSPENSION; COMPARATIVE STUDY; CONTROLLED STUDY; CPG ISLAND; FEMALE; HISTOLOGY; IMMUNOSTIMULATION; LEUKOCYTE; LYMPHOCYTE; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL; TUMOR GROWTH;

EID: 24144434714     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1159/000087380     Document Type: Article

References (42)

1. Huland H: Harnblasenkarzinom; in Hautmann RE, Huland H (eds): Urologie. Heidelberg, Springer, 2001, pp 201-212.
2. Heney NM: Natural history of superficial bladder cancer. Prognostic features and long-term disease course. Urol Clin North Am 1992;19:429-433.
3. Amling CL: Diagnosis and management of superficial bladder cancer. Curr Probl Cancer 2001;25:219-278.
4. Sylvester RJ, Oosterlinck W, van der Meijden AP: A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol 2004;171:2186-2190.
5. Malmstrom PU: Intravesical therapy of superficial bladder cancer. Crit Rev Oncol Hematol 2003;47:109-126.
6. Sylvester RJ, van der Meijden AP, Lamm DL: Intravesical bacillus Calmette-Guérin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002;168:1964-1970.
7. Bohle A, Bock PR: Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology 2004;63:682-686.
8. Andius P, Holmang S: Bacillus Calmette-Guérin therapy in stage Ta/T1 bladder cancer: prognostic factors for time to recurrence and progression. BJU Int 2004;93:980-984.
9. Bohle A, Brandau S: Immune mechanisms in bacillus Calmette-Guérin immunotherapy for superficial bladder cancer. J Urol 2003;170:964-969.
10. De Boer EC, Rooijakkers SJ, Schamhart DH, Kurth KH: Cytokine gene expression in a mouse model: the first instillations with viable bacillus Calmette-Guérin determine the succeeding Th1 response. J Urol 2003;170:2004-2008.
11. Sanchez-Carbayo M, Urrutia M, Romani R, Herrero M, Gonzalez de Buitrago JM, Navajo JA: Serial urinary IL-2, IL-6, IL-8, TNFalpha, UBC, CYFRA 21-1 and NMP22 during follow-up of patients with bladder cancer receiving intravesical BCG. Anticancer Res 2001;21:3041-3047.
12. Tokunaga T, Yamamoto H, Shimada S, Abe H, Fukuda T, Fujisawa Y, Furutani Y, Yano O, Kataoka T, Sudo T, et al: Antitumor activity of deoxyribonucleic acid fraction from Mycobacterium bovis BCG. 1. Isolation, physicochemical characterization, and antitumor activity. J Natl Cancer Inst 1984;72:955-962.
13. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, Matsumoto M, Hoshino K, Wagner H, Takeda K, Akira S: A Toll-like receptor recognizes bacterial DNA. Nature 2000;408:740-745.
14. Ulevitch RJ: Therapeutics targeting the innate immune system. Nat Rev Immunol 2004;4:512-520.
15. Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, Koretzky GA, Klinman DM: CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995;374:546-549.
16. Dalpke A, Zimmermann S, Heeg K: CpG DNA in the prevention and treatment of infections. BioDrugs 2002;16:419-431.
17. Hegele A, Dalpke A, Barth P, Varga Z, Heeg K, Hofmann R, Olbert P: Antineoplastic effect of immunostimulatory DNA (CpG-ODN) in a murine C57-BL6/MB-49 transitional cell carcinoma model. Anticancer Res 2004;24:2225-2230.
18. Ninalga C, Loskog A, Klevenfeldt M, Essand M, Totterman TH: CpG oligonucleotide therapy cures subcutaneous and orthotopic tumors and evokes protective immunity in murine bladder cancer. J Immunother 2005;28:20-27.
19. Heckelsmiller K, Rall K, Beck S, Schlamp A, Seiderer J, Jahrsdorfer B, Krug A, Rothenfusser S, Endres S, Hartmann G: Peritumoral CpG DNA elicits a coordinated response of CD8 T cells and innate effectors to cure established tumors in a murine colon carcinoma model. J Immunol 2002;169:3892-3899.
20. Whitmore MM, DeVeer MJ, Edling A, Oates RK, Simons B, Lindner D, Williams BR: Synergistic activation of innate immunity by double-stranded RNA and CpG DNA promotes enhanced antitumor activity. Cancer Res 2004;64:5850-5860.
21. Summerhayes IC, Franks LM: Effects of donor age on neoplastic transformation of adult mouse bladder epithelium in vitro. J Natl Cancer Inst 1979;62:1017-1023.
22. Soloway MS: Intravesical and systemic chemotherapy of murine bladder cancer. Cancer Res 1977;37:2918-2929.
23. Ratliff TL, Gillen D, Catalona WJ: Requirement of a thymus dependent immune response for BCG-mediated antitumor activity. J Urol 1987;137:155-158.
24. Gunther JH, Jurczok A, Wulf T, Brandau S, Deinert I, Jocham D, Bohle A: Optimizing syngeneic orthotopic murine bladder cancer (MB49). Cancer Res 1999;59:2834-2837.
25. Zlotta AR, Van Vooren JP, Denis O, Drowart A, Daffe M, Lefevre P, Schandene L, De Cock M, De Bruyn J, Vandenbussche P, Jurion F, Palfliet K, Simon J, Schulman CC, Content J, Huygen K: What are the immunologically active components of bacille Calmette-Guérin in therapy of superficial bladder cancer? Int J Cancer 2000;87:844-852.
26. Yamamoto S, Yamamoto T, Kataoka T, Kuramoto E, Yano O, Tokunaga T: Unique palindromic sequences in synthetic oligonucleotides are required to induce IFN [correction of INF] and augment IFN-mediated [correction of INF] natural killer activity. J Immunol 1992;148:4072-4076.
27. Krieg AM: CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 2002;20:709-760.
28. Uhlmann E, Vollmer J: Recent advances in the development of immunostimulatory oligonucleotides. Curr Opin Drug Discov Devel 2003;6:204-217.
29. Baines J, Celis E: Immune-mediated tumor regression induced by CpG-containing oligodeoxynucleotides. Clin Cancer Res 2003;9: 2693-2700.
30. Jahrsdorfer B, Weiner GJ: CpG oligodeoxynucleotides for immune stimulation in cancer immunotherapy. Curr Opin Investig Drugs 2003;4:686-690.
31. Stacey KJ, Sweet MJ, Hume DA: Macrophages ingest and are activated by bacterial DNA. J Immunol 1996;157:2116-2122.
32. Bauer S, Kirschning CJ, Hacker H, Redecke V, Hausmann S, Akira S, Wagner H, Lipford GB: Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc Natl Acad Sci USA 2001;98: 9237-9242.
33. Hegele A, Dalpke A, von Knobloch R, Heeg K, Hofmann R, Olbert P: No direct pro-apoptotic effect of immunostimulative DNA (CpG ODN) on MB49 transitional cell carcinoma cells in vitro. Eur Urol 2004,3:211.
34. Olbert P, Dalpke A, Schrader A, Heeg K, Hofmann R, Hegele A: Toll-like receptor expression in MB-49 transitional cell carcinoma cells in culture. Onkologie 2004;27:146.
35. Platz J, Beisswenger C, Dalpke A, Koczulla R, Pinkenburg O, Vogelmeier C, Bals R: Microbial DNA induces a host defense reaction of human respiratory epithelial cells. J Immunol 2004;173:1219-1223.
36. Olbert P, Hegele A, Dalpke A, Barth P, Heeg K. Hofmann R: Is local immunostimulation of the bladder wall by CpG-oligodeoxynucleotides (CpG-ODN) possible? First histological evidence in C3H/HE-N mice. J Urol 2003;169: 138.
37. Hartmann G, Weeratna RD, Ballas ZK, Payette P, Blackwell S, Suparto I, Rasmussen WL, Waldschmidt M, Sajuthi D, Purcell RH, Davis HL, Krieg AM: Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. J Immunol 2000;164:1617-1624.
38. Dalpke AH, Zimmermann S, Albrecht I, Heeg K: Phosphodiester CpG oligonucleotides as adjuvants: polyguanosine runs enhance cellular uptake and improve immunostimulative activity of phosphodiester CpG oligonucleotides in vitro and in vivo. Immunology 2002; 106:102-112.
39. Friedberg JW, Kim H, McCauley M, Hessel EM, Sims P, Fisher DC, Nadler LM, Coffman RL, Freedman AS: Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin's lymphoma: increased interferon-alpha/beta-inducible gene expression, without significant toxicity. Blood 2005;105:489-495.
40. Leifer CA, Verthelyi D, Klinman DM: Heterogeneity in the human response to immunostimulatory CpG oligodeoxynucleotides. J Immunother 2003;26:313-319.
41. Paul S: Technology evaluation: CpG-7909, Coley. Curr Opin Mol Ther 2003;5:553-559.
42. Bohle B: AIC. Dynavax. Curr Opin Investig Drugs 2003;4:603-607.